Day: March 18, 2025

SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results. Fourth Quarter and Full Year 2024 Financial ResultsCash, cash equivalents and investments: Cash, cash equivalents and investments as of December 31, 2024, were $112.4 million. R&D Expenses: Research and development expenses were $8.4 million for the fourth quarter of 2024, which includes non-cash stock-based compensation expense of $0.7 million. For the full year of 2024, research and development expenses were $48.7 million, which includes non-cash stock-based compensation expense of $3.4 million. G&A Expenses: General and administrative expenses were $4.9 million for the fourth quarter of 2024, which includes non-cash...

Highlights of the fiscal year include:Revenue of $1.20 billion, an increase of 20% compared to $999.6 million in FY24. Net income of $96.7 million, an increase of 74% compared to $55.7 million in FY24, with non-GAAP net income of $277.3 million, an increase of 42% compared to $195.5 million in FY24. Net income per diluted share of $1.09, an increase of 70% compared to $0.64 in FY24, with non-GAAP net income per diluted share of $3.12, an increase of 39% compared to $2.25 in FY24. Adjusted EBITDA of $471.8 million, an increase of 28% compared to $369.2 million in FY24. 9.9 million HSAs, an increase of 14% compared to FY24. Total HSA Assets of $32.1 billion, an increase of 27% compared to FY24. 17.0 million Total Accounts, including both HSAs and complementary CDBs, an increase of 9% compared to FY24. The Company completed its acquisition...